Jia-Lie Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jia-Lie Luo has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Qing Zhu
School of Pharmacy Nantong University Nantong Jiangsu China
3 shared publications - Liyun Wang
School of Pharmacy, Nantong University, No. 9, Seyuan Road, Nantong 226001, China
2 shared publications - Xiao-Dan Zhang
School of Pharmacy, Nantong University, No. 9, Seyuan Road, Nantong 226001, China
2 shared publications - Bo-Yi Fan
School of Pharmacy, Nantong University, 9 Seyuan Road, Nantong 226019, China
1 shared publication - Danfeng Gong
Department of Pharmacology, School of Pharmacy, Nantong University, Nantong 226001, China
1 shared publication Guang-Tong Chen
School of Pharmacy, Nantong University, 9 Seyuan Road, Nantong, 226019, People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 8 September 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1290
Translating Alzheimer’s Disease Mechanisms into Therapeutic Opportunities
Alzheimer’s disease (AD), characterized by progressive cognitive decline and functional impairment, is the most prevalent cause of dementia, and it poses a significant socioeconomic and caregiving burden on patients, families, and healthcare systems. Notwithstanding comprehensive research, the precise causes underlying AD remain ambiguous. Evidence increasingly indicates that AD is a multifactorial and heterogeneous disease involving a mix of genetic and environmental factors. The amyloid-cascade hypothesis, neuroinflammation and immunity, vascular pathology, and oxidative stress all fulfill significant functions in the onset and development of AD. This review primarily examines the critical pathogenesis, key biomarkers, and novel therapeutic strategies of Alzheimer’s disease to inform future research directions.
- 8 September 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (9) , 1290
Open AccessTranslating Alzheimer’s Disease Mechanisms into Therapeutic Opportunities
Alzheimer’s disease (AD), characterized by progressive cognitive decline and functional impairment, is the most prevalent cause of dementia, and it poses a significant socioeconomic and caregiving burden on patients, families, and healthcare systems. Notwithstanding comprehensive research, the precise causes underlying AD remain ambiguous. Evidence increasingly indicates that AD is a multifactorial and heterogeneous disease involving a mix of genetic and environmental factors. The amyloid-cascade hypothesis, neuroinflammation and immunity, vascular pathology, and oxidative stress all fulfill significant functions in the onset and development of AD. This review primarily examines the critical pathogenesis, key biomarkers, and novel therapeutic strategies of Alzheimer’s disease to inform future research directions.
- Top Cited PapersOpen Access
- 8 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5123
Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF
Adult neurogenesis in the dentate gyrus (DG) is impaired during Alzheimer’s disease (AD) progression. Curcumin has been reported to reduce cell apoptosis and stimulate neurogenesis. This study aimed to investigate the influence of curcumin on adult neurogenesis in AD mice and its potential mechanism. Two-month-old male C57BL/6J mice were injected with soluble β-amyloid (Aβ1–42) using lateral ventricle stereolocalization to establish AD models. An immunofluorescence assay, including bromodeoxyuridine (BrdU), doublecortin (DCX), and neuron-specific nuclear antigen (NeuN), was used to detect hippocampal neurogenesis. Western blot and an enzyme-linked immunosorbent assay (ELISA) were used to test the expression of related proteins and the secretion of brain-derived neurotrophic factor (BDNF). A Morris water maze was used to detect the cognitive function of the mice. Our results showed that curcumin administration (100 mg/kg) rescued the impaired neurogenesis of Aβ1–42 mice, shown as enhanced BrdU+/DCX+ and BrdU+/NeuN+ cells in DG. In addition, curcumin regulated the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) -mediated glycogen synthase kinase-3β (GSK3β) /Wingless/Integrated (Wnt)/β-catenin pathway and cyclic adenosine monophosphate response element-binding protein (CREB)/BDNF in Aβ1–42 mice. Inhibiting Wnt/β-catenin and depriving BDNF could reverse both the upregulated neurogenesis and cognitive function of curcumin-treated Aβ1–42 mice. In conclusion, our study indicates that curcumin, through targeting PI3K/Akt, regulates GSK3β/Wnt/β-catenin and CREB/BDNF pathways, improving the adult neurogenesis of AD mice.
- 8 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5123
Top Cited PapersOpen AccessCurcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF
Adult neurogenesis in the dentate gyrus (DG) is impaired during Alzheimer’s disease (AD) progression. Curcumin has been reported to reduce cell apoptosis and stimulate neurogenesis. This study aimed to investigate the influence of curcumin on adult neurogenesis in AD mice and its potential mechanism. Two-month-old male C57BL/6J mice were injected with soluble β-amyloid (Aβ1–42) using lateral ventricle stereolocalization to establish AD models. An immunofluorescence assay, including bromodeoxyuridine (BrdU), doublecortin (DCX), and neuron-specific nuclear antigen (NeuN), was used to detect hippocampal neurogenesis. Western blot and an enzyme-linked immunosorbent assay (ELISA) were used to test the expression of related proteins and the secretion of brain-derived neurotrophic factor (BDNF). A Morris water maze was used to detect the cognitive function of the mice. Our results showed that curcumin administration (100 mg/kg) rescued the impaired neurogenesis of Aβ1–42 mice, shown as enhanced BrdU+/DCX+ and BrdU+/NeuN+ cells in DG. In addition, curcumin regulated the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) -mediated glycogen synthase kinase-3β (GSK3β) /Wingless/Integrated (Wnt)/β-catenin pathway and cyclic adenosine monophosphate response element-binding protein (CREB)/BDNF in Aβ1–42 mice. Inhibiting Wnt/β-catenin and depriving BDNF could reverse both the upregulated neurogenesis and cognitive function of curcumin-treated Aβ1–42 mice. In conclusion, our study indicates that curcumin, through targeting PI3K/Akt, regulates GSK3β/Wnt/β-catenin and CREB/BDNF pathways, improving the adult neurogenesis of AD mice.
- Top Cited PapersOpen Access
- 5 November 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 168, 115800
Current status of GABA receptor subtypes in analgesia
- 5 November 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 168, 115800
Top Cited PapersOpen AccessCurrent status of GABA receptor subtypes in analgesia
- Open Access
- 19 May 2023
- Published by MDPI AG in Preprints.org
GABA Receptor Subtypes Involvement of Analgesia: Current Status
Gamma-aminobutyric acid (GABA), a non-protein-producing amino acid, is extensively found in microorganisms, plants and vertebrates, and is abundantly expressed in the spinal cord and brain. To date, GABA is considered to be the major inhibitory neurotransmitter in the central nervous system. Its physiological effects are related to the regulation of synaptic transmission, the promotion of neuronal development and relaxation, and the prevention of insomnia and depres-sion. Mediated through its specific receptors, it plays a pivotal role in the control of neuronal ex-citability, which can serve as anovel target for developing analgesics for pain management. This review provides an update on the accumulating evidence of specific GABA receptors and their subtypes in the involvement of pain analgesia.
- 19 May 2023
- Published by MDPI AG in Preprints.org
Open AccessGABA Receptor Subtypes Involvement of Analgesia: Current Status
Gamma-aminobutyric acid (GABA), a non-protein-producing amino acid, is extensively found in microorganisms, plants and vertebrates, and is abundantly expressed in the spinal cord and brain. To date, GABA is considered to be the major inhibitory neurotransmitter in the central nervous system. Its physiological effects are related to the regulation of synaptic transmission, the promotion of neuronal development and relaxation, and the prevention of insomnia and depres-sion. Mediated through its specific receptors, it plays a pivotal role in the control of neuronal ex-citability, which can serve as anovel target for developing analgesics for pain management. This review provides an update on the accumulating evidence of specific GABA receptors and their subtypes in the involvement of pain analgesia.